D-Index & Metrics Best Publications

James P. Allison

The University of Texas MD Anderson Cancer Center
United States

Immunology

USA

2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Immunology D-index 149 Citations 105,954 487 World Ranking 56 National Ranking 40

Medicine D-index 155 Citations 109,309 546 World Ranking 511 National Ranking 307

Research.com Recognitions

Awards & Achievements

2023 - Research.com Immunology in United States Leader Award

2019 - Benjamin Franklin Medal, Franklin Institute

2019 - Distinguished Fellows of the American Association of Immunologists (AAI)

2018 - Nobel Prize for their discovery of cancer therapy by inhibition of negative immune regulation

2018 - King Faisal Prize

2018 - Albany Medical Center Prize in Medicine and Biomedical Research

2018 - Jessie Stevenson Kovalenko Medal, US National Academy of Sciences For important medical discoveries related to the body’s immune response to tumors.

2018 - Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson for pioneering a novel and effective strategy to harness the immune system for treating solid tumor cancers.

2017 - Fellow of the American Academy of Arts and Sciences

2017 - BBVA Foundation Frontiers of Knowledge Award

2015 - Paul Ehrlich and Ludwig Darmstaedter Prize

2014 - Canada Gairdner International Award

2014 - Breakthrough Prize in Life Sciences for the discovery of T cell checkpoint blockade as effective cancer therapy.

2014 - Szent-Györgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research (NFCR)

2014 - Louisa Gross Horwitz Prize, Columbia University

2011 - American Association of Immunologists Lifetime Achievement Award

2011 - AAI Lifetime Achievement Award, American Association of Immunologists

2008 - AAI-Steinman Award for Human Immunology Research, American Association of Immunologists

2007 - Member of the National Academy of Medicine (NAM)

2006 - Fellow of the American Association for the Advancement of Science (AAAS)

1997 - Member of the National Academy of Sciences

1930 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is he best known for?

The fields of study he is best known for:

Gene
Cancer
Immune system

His primary scientific interests are in Immunology, T cell, Cytotoxic T cell, Antigen and Immune system. His biological study spans a wide range of topics, including Blockade and Melanoma. The study incorporates disciplines such as Molecular biology, Tremelimumab and Cell biology in addition to T cell.

In his research on the topic of Cytotoxic T cell, FOXP3 is strongly related with CD8. His study focuses on the intersection of Antigen and fields such as Antibody with connections in the field of Nivolumab. His Immune system research incorporates themes from Mutation, Cancer and Cancer research.

His most cited work include:

Restoring function in exhausted CD8 T cells during chronic viral infection (2941 citations)
Enhancement of antitumor immunity by CTLA-4 blockade. (2458 citations)
The future of immune checkpoint therapy (2293 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Immunology, T cell, Immune system, Antigen and Cytotoxic T cell. His Immunology research includes elements of Cancer, Cancer research and Blockade. His T cell research includes themes of Receptor, CD8 and Cell biology.

His studies in Immune checkpoint and Immunity are all subfields of Immune system research. His Antigen study integrates concerns from other disciplines, such as Molecular biology, Antibody and Cellular differentiation. His Cytotoxic T cell study often links to related topics such as FOXP3.

He most often published in these fields:

Immunology (45.64%)
T cell (35.06%)
Immune system (28.94%)

What were the highlights of his more recent work (between 2016-2021)?

Internal medicine (19.67%)
Cancer research (22.63%)
Oncology (16.33%)

In recent papers he was focusing on the following fields of study:

James P. Allison mainly focuses on Internal medicine, Cancer research, Oncology, Immune checkpoint and Immune system. His research integrates issues of T cell, CD8 and Immunotherapy in his study of Cancer research. His work deals with themes such as Cytotoxic T cell and Antigen, which intersect with T cell.

As a member of one scientific family, James P. Allison mostly works in the field of Oncology, focusing on Ipilimumab and, on occasion, Prostate cancer. Blockade, Cancer and Immunology are the main areas of his Immune checkpoint studies. His work carried out in the field of Immune system brings together such families of science as Receptor, Antibody and Cytokine.

Between 2016 and 2021, his most popular works were:

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients (1381 citations)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy (844 citations)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade (514 citations)

In his most recent research, the most cited papers focused on:

Gene
Cancer
Immune system

His scientific interests lie mostly in Immune checkpoint, Cancer research, Immunotherapy, Melanoma and Cancer. His studies deal with areas such as Ipilimumab and Oncology as well as Immune checkpoint. The concepts of his Cancer research study are interwoven with issues in T cell, CD8, Immune system and Cytotoxic T cell.

His T cell research integrates issues from Precision medicine, Targeted therapy and Antigen. His study in the field of CTLA-4 and T cell differentiation also crosses realms of Context. His Immunology study combines topics from a wide range of disciplines, such as Microbiome and Feces.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Restoring function in exhausted CD8 T cells during chronic viral infection.

Daniel L. Barber;E. John Wherry;David Masopust;Baogong Zhu.
Nature (2006)

4356 Citations

Enhancement of antitumor immunity by CTLA-4 blockade.

Dana R. Leach;Matthew F. Krummel;James P. Allison.
Science (1996)

3798 Citations

The future of immune checkpoint therapy

Padmanee Sharma;James P. Allison.
Science (2015)

3606 Citations

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

V. Gopalakrishnan;V. Gopalakrishnan;C. N. Spencer;C. N. Spencer;L. Nezi;A. Reuben.
Science (2018)

2672 Citations

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Matthew F. Krummel;James P. Allison.
Journal of Experimental Medicine (1995)

2373 Citations

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.

Fiona A. Harding;James G. McArthur;Jane A. Gross;David H. Raulet.
Nature (1992)

2099 Citations

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

Michael A. Postow;Margaret K. Callahan;Margaret K. Callahan;Christopher A. Barker;Christopher A. Barker;Yoshiya Yamada;Yoshiya Yamada.
The New England Journal of Medicine (2012)

1894 Citations

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.

Berna C. Özdemir;Berna C. Özdemir;Tsvetelina Pentcheva-Hoang;Julienne L. Carstens;Xiaofeng Zheng.
Cancer Cell (2014)

1877 Citations

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

Padmanee Sharma;James P. Allison.
Cell (2015)

1867 Citations

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Giao Q. Phan;James C. Yang;Richard M. Sherry;Patrick Hwu.
Proceedings of the National Academy of Sciences of the United States of America (2003)

1816 Citations

If you think any of the details on this page are incorrect, let us know.